Oncology References:

1. Data on file.

2. Sung H, Ferlay J, Siegel R, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2021;71(3):209-49.

3. Ros J, Balconi F, Baraibar, I, et al. Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer. *Front Oncol*. 2023;13:1112276.

4. Data on file.

5. Adamska A, Domenichini A, Falasca M. Pancreatic ductal adenocarcinoma: current and evolving therapies. *Int J Mol Sci*. 2017;18(7):1338.

6. Stoop TF, Javed AA, Oba A, et al. Pancreatic cancer. *Lancet*. 2025;405(10485):1182-202.

7. Sobhani N, Pittacolo M, D'Angelo A, Marchegiani G. Recent anti-$KRAS^{G12D}$ therapies: A "possible impossibility" for pancreatic ductal adenocarcinoma. *Cancers (Basel)*. 2025;17(4):704.

8. St Laurent J, Liu JF. Treatment approaches for platinum-resistant ovarian cancer. *J Clin Oncol*. 2023;42:127-33.

9. El Bairi K, Madariaga A, Trapani D, Jarroudi OA, Afqir S. New horizons for platinum-resistant ovarian cancer: insights from ASCO and ESMO. *Int J Gynecol Cancer*. 2024;34(5):760-72.

10. Wang CC, Gomez-Roas M, Hinchcliff EM. Emerging therapeutic targets for platinum-resistant ovarian cancer. *Hematol Oncol Clin North Am*. 2025;39(6):1057-75.

11. Richardson DL, Eskander RN, O'Malley DM. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance. *JAMA Oncol*. 2023;9(6):851-9.